Dividend Declaration - On 14 April 2025, INVL Baltic Farmland, AB announced a dividend allocation of EUR 0.12 per share [1] Dividend Payment Process - Dividends will be paid to shareholders who held shares by 29 April 2025, the tenth business day after the General Shareholders Meeting [1] - From 14 May 2025, dividends will be allocated to shareholders based on their shareholding accounts with financial brokerage companies or credit institutions, after applicable withholding taxes [2] Taxation on Dividends - For the year 2024, dividends paid to natural persons who are residents of Lithuania or foreign countries are subject to a 15% withholding Personal income tax [3] - Dividends paid to legal entities in Lithuania or foreign countries are subject to a 16% withholding Corporate income tax, unless specified otherwise by law [3] Contact Information - For additional information regarding dividend payouts, shareholders can contact Artea Bankas AB at +370 610 44447 [4] - The authorized contact person for further inquiries is Director Egle Surplienė, reachable via email at egle.surpliene@invaldainvl.com [4]

Core Viewpoint - Galapagos is re-evaluating its previously announced separation into two entities due to regulatory and market developments, focusing on maximizing resources for transformative business development transactions [3][4]. Group 1: Strategic Update - The company plans to explore all strategic alternatives for its existing businesses, including cell therapy, to enhance resource allocation for business development [3][4]. - The Board of Directors has appointed Mr. Henry Gosebruch as the new CEO, effective immediately, succeeding Dr. Paul Stoffels, who will retire in April 2025 [4][6]. - Mr. Jérôme Contamine has been appointed as the Chair of the Board of Directors, replacing Dr. Paul Stoffels [5][7]. Group 2: Leadership Transition - Mr. Gosebruch will lead the strategic evaluation process for Galapagos' current business while also focusing on building a pipeline of innovative medicines [4][6]. - Dr. Paul Stoffels will remain with the company in an advisory role, assisting in evaluating strategic options for the cell therapy pipeline, including the flagship program GLPG5101 [6][7]. Group 3: Future Directions - The company is currently assessing strategic options regarding its clinical programs and other assets, including potential mergers, divestitures, and out-licensing [7]. - The goal is to leverage the company's strong balance sheet and cash resources to pursue transformative business development opportunities [4][7].

Core Viewpoint - The company reported a challenging Q1 2025 with a slight decline in revenue and organic growth, influenced by geopolitical uncertainties and tariff impacts, but maintains its financial guidance for 2025 [1][3]. Financial Highlights - Revenue for Q1 2025 was €256.5 million, down from €259.0 million in Q1 2024, reflecting a negative organic growth of 1.2% compared to 3.7% in the previous year [2]. - Gross margin improved to 43.2%, up from 41.8% in Q1 2024, supported by a favorable price and product mix [2][7]. - Overhead costs increased to €95.8 million, resulting in an overhead cost ratio of 37.3%, compared to 34.5% in Q1 2024 [2]. - EBITDA before special items decreased to €31.3 million, with an EBITDA margin of 12.2%, down from 13.2% [2][7]. - Free cash flow was negative at €19.8 million, compared to negative €7.4 million in Q1 2024 [2][8]. - Basic earnings per share (EPS) fell to €0.08 from €0.34 in the previous year [2]. Regional Performance - EMEA region showed strong organic growth of 7.9%, while APAC reported moderate growth of 2.9%. In contrast, the Americas experienced a significant decline of 17.7% due to a high backlog release and soft demand [4][6]. - The Professional Business was notably impacted by a revenue decrease in the US high-pressure washer segment [4][6]. Financial Outlook - The financial outlook for 2025 remains unchanged, with expected organic growth between 1% and 3% and an EBITDA margin before special items projected between 13% and 14% [3][5]. - The company plans to implement a targeted overhead cost reduction program starting in Q2 2025 to address recent cost trends [7]. Tariff and Supply Chain Management - The CEO highlighted that tariffs have complicated operations but the company’s flexible supply chain mitigates most of the tariff exposure, with remaining impacts to be offset through price adjustments [1][5].

Core Points - Aalberts has repurchased 141,063 shares from May 5, 2025, to May 9, 2025, for a total of EUR 4,056,005.58, averaging EUR 28.75 per share [1] - The cumulative total of shares repurchased under the buyback program has reached 1,793,728 shares for a total consideration of EUR 53,525,045 [2] - The share buyback program is part of a larger initiative announced on February 27, 2025, with a total budget of EUR 75 million, set to conclude by October 24, 2025 [1][2] - The buyback is being conducted in compliance with the authority granted by the Annual General Meeting on May 23, 2024, and adheres to the Market Abuse Regulation [3] Additional Information - An intermediary has been engaged to facilitate the share repurchase in the open market, independent of Aalberts [2] - The company intends to cancel the shares following their repurchase [1] - Weekly progress of the buyback program can be tracked on the company's website [3]

Core Insights - Coop Pank experienced strong growth in its loan portfolio due to a significant issuance of business and home loans in April 2025 [1] - The bank's loan portfolio quality remains robust despite economic uncertainties, with a new leasing product introduced for used vehicle financing [2] - A deliberate reduction in deposit volume was linked to a successful issuance of covered bonds, providing a stable funding source [3] Financial Performance - The number of clients increased by 1,700 to reach 214,400, while active clients decreased by 100, marking a 12% growth in the customer base year-over-year [5] - Customer deposits decreased by 107 million euros to 1.81 billion euros, with corporate deposits down by 74 million euros and private deposits down by 5 million euros [5] - The loan portfolio grew by 53 million euros to 1.87 billion euros, with business loans increasing by 39 million euros and home loans by 13 million euros [5] - The bank's net profit for April was 1.8 million euros, with a 19% decrease in net profit for the first four months compared to the previous year [5] - Return on equity stood at 10.3% and the cost-income ratio was 53% in April [5]

Core Insights - IBA has launched CASSY, a compact synthesizer aimed at revolutionizing radiopharmaceutical production processes, particularly for radiometals and radiotracers [1][5]. Group 1: Product Features - CASSY enhances efficiency in radiopharmaceutical production through seamless integration into laboratory workflows, user-friendly interfaces, and versatility for purification and radiolabelling [2]. - The compact design allows stacking of up to six units in a single standard hot cell, optimizing space and increasing production potential, making it suitable for laboratories with limited space [3]. - CASSY is adaptable for a wide range of radioisotopes, catering to diverse research and clinical needs, and is positioned for future innovations like radiotheranostics [3]. Group 2: Components and Technology - CASSY utilizes specific cassettes developed by Fluidomica, which include all necessary components for radioisotope and radiopharmaceutical manufacturing processes [4]. - The cassettes are designed for single use, ensuring efficiency and reliability in production [4]. Group 3: Company Commitment and Leadership - Charles Kumps, President of IBA RadioPharma Solutions, emphasized that CASSY represents a significant advancement in theranostic innovation, enhancing the quality and reliability of radiopharmaceutical manufacturing [5]. - IBA continues to lead the radiopharmaceutical industry through its commitment to innovation and improving healthcare outcomes globally [5]. Group 4: Company Overview - IBA is recognized as the world leader in particle accelerator technology and is a major supplier in proton therapy, industrial sterilization, and dosimetry, employing approximately 2,100 people worldwide [7]. - The company is listed on the EURONEXT stock exchange and is a certified B Corporation, meeting high standards of social and environmental performance [8].

Core Insights - Kuros Biosciences is set to present its latest developments regarding MagnetOs and its strategic priorities during the Capital Markets Day on May 13, 2025, in Zürich, Switzerland [1][2] Company Overview - Kuros Biosciences is a leader in innovative biologic technologies, focusing on bone healing solutions [1][9] - The company is expanding its global footprint and targeting both spinal and extremity markets, with anticipated growth in the U.S., Europe, and other regions [6] Product Insights - MagnetOs is a proprietary bone healing technology that has shown nearly double the fusion rate compared to autograft in a Level I human clinical study, particularly effective among active smokers [6][7] - The technology utilizes NeedleGrip™, a submicron surface technology that stimulates bone growth without added cells or growth factors [6][7] Strategic Priorities - Kuros aims to improve patient outcomes and drive shareholder value through innovation, strategic partnerships, and global growth [4][6] - The company is leveraging its alliance with Medtronic to enhance market access and accelerate product adoption [6] Clinical Insights - Seven Level I human clinical trials are currently underway to demonstrate MagnetOs' efficacy in promoting bone growth and fusion across various surgical applications [6] - Insights from Dr. Greg Berlet, a leading orthopedic surgeon, will be shared, highlighting the advantages of MagnetOs from both surgeon and patient perspectives [2][6]

Core Insights - LHV Group reported strong financial performance in April, with significant growth in both loan and deposit portfolios, alongside a net profit of EUR 10.8 million [1][2] Financial Performance - The consolidated loan portfolio of LHV Group increased by EUR 77 million, while total deposits rose by EUR 727 million in April [1] - The net profit for LHV Group was EUR 10.8 million, with contributions from subsidiaries: AS LHV Pank (EUR 10.1 million), LHV Bank Ltd (EUR 83 thousand), AS LHV Kindlustus (EUR 319 thousand), and AS LHV Varahaldus (EUR 68 thousand) [2] - The return on equity attributable to shareholders was 19.1% [2] Customer Growth and Deposits - LHV Pank gained 2,800 new customers in April, with a loan portfolio growth of EUR 53 million and deposits increasing by EUR 574 million [3] - The increase in deposits included EUR 41 million from retail customers and EUR 212 million from corporate customers, with an additional EUR 120 million from platform deposits [3] Ratings and Recognition - Moody's Ratings upgraded LHV Pank's covered bond programme and ratings to the highest Aaa level [4] - LHV was recognized as one of the leading employers in the financial sector for the fifth consecutive year, ranking second in the overall assessment [4] UK Operations - LHV Bank in the UK saw rapid growth, with a loan portfolio increase of EUR 24 million and platform deposits rising by EUR 130 million [5] - The bank's profit was affected by increased marketing expenses for an upcoming retail banking campaign [5] Insurance and Investment Management - LHV Kindlustus signed new insurance contracts worth EUR 3.7 million, with claims paid totaling EUR 2.1 million [6] - The pension funds managed by LHV maintained their value despite market tensions, with larger funds showing year-to-date returns of 3.4% and 4.1% [7] Capital and Credit Ratings - LHV Group issued EUR 50 million in Tier 1 capital to support growth and repurchase previous AT1 bonds [8] - The long-term issuer rating for LHV Group remains Baa3 with a positive outlook [8] Company Overview - LHV Group is the largest domestic financial group in Estonia, with key subsidiaries including LHV Pank, LHV Varahaldus, LHV Kindlustus, and LHV Bank Limited [9] - As of the end of April, LHV served 468,000 banking clients, managed pension funds for 113,000 active clients, and provided insurance for 176,000 clients [9]

Core Insights - EfTEN Real Estate Fund AS reported strong financial results in April, with consolidated rental income reaching 2,611 thousand euros, a month-over-month increase of 55 thousand euros driven by new rental payments from the ICONFIT logistics centre and the Hiiu elderly care home [1] - The Fund's EBITDA for April was 2,183 thousand euros, reflecting a month-over-month increase of 193 thousand euros due to higher rental income and lower expenses [2] - The Fund paid a record dividend of 12.7 million euros in April, or 1.11 euros per share, partially financed by refinancing bank loans totaling 6.3 million euros [3] - The weighted average interest rate decreased to 4.21% in April from 4.37% in March, with a year-over-year decrease in consolidated interest expense of 586 thousand euros [4] - For the first four months of 2025, consolidated rental income was 10.3 million euros, a 1% year-over-year increase, while consolidated EBITDA was 8.4 million euros, down from 8.6 million euros in the same period last year [5] - The Fund's net asset value (NAV) per share was 19.64 euros at the end of April, with an EPRA NRV of 20.50 euros; the NAV decreased by 5.3% due to the dividend distribution [6]

Core Insights - Roche, in collaboration with the Breast International Group (BIG) and other partners, announced significant overall survival results from the phase III APHINITY study for HER2-positive early-stage breast cancer, showing a 17% reduction in the risk of death after ten years for patients treated with a Perjeta-based regimen compared to those receiving Herceptin and chemotherapy [1][2][6]. Study Results - The APHINITY study demonstrated that 91.6% of patients treated with the Perjeta-based regimen were alive at ten years, compared to 89.8% for the control group, with a hazard ratio of 0.83 [6]. - A 21% reduction in the risk of death was observed in the subgroup of patients with lymph node-positive disease, with a hazard ratio of 0.79 [6][5]. - The previously reported invasive disease-free survival benefit was maintained, reinforcing earlier analyses [6][5]. Treatment Implications - The results validate the Perjeta-based regimen as a standard-of-care treatment for high-risk HER2-positive breast cancer patients, particularly those with lymph node-positive disease [2][4]. - Roche's commitment to improving outcomes for HER2-positive breast cancer patients is evident through the development of targeted therapies like Herceptin and Perjeta, which have transformed survival rates [11][10]. Future Presentations - Full results from the APHINITY study will be presented as a late-breaking abstract at the 2025 European Society for Medical Oncology Breast Cancer Congress [3].